modelD11AC06

Diagram of D11AC06

Extends from Pharmacokinetic.Models.PK_1C.

Information

name:PovidoneIodine
ATC code:D11AC06
route:topical
compartments:1
dosage:1000mg
volume of distribution:1L
clearance:0
other parameters in model implementation

Povidone-iodine is an antiseptic and disinfectant used primarily for skin disinfection before and after surgery, for wound cleaning, and to treat minor infections. It is a complex of polyvinylpyrrolidone and elemental iodine, providing a slow release of iodine. Povidone-iodine is widely used topically and is approved for such uses in many countries.

Pharmacokinetics

No explicit pharmacokinetic model data for povidone-iodine exists in literature as it is used almost exclusively topically and is minimally absorbed systemically. No population-, age-, or sex-specific PK data reported.

References

  1. Lin, YS, et al., & Milgrom, P (2018). Pharmacokinetics of Iodine and Fluoride following Application of an Anticaries Varnish in Adults. JDR clinical and translational research 3(3) 238–245. DOI:10.1177/2380084418771930 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30938600

  2. Below, H, et al., & Rudolph, P (2006). Systemic iodine absorption after preoperative antisepsis using povidone-iodine in cataract surgery-- an open controlled study. Dermatology (Basel, Switzerland) 212 Suppl 1 41–46. DOI:10.1159/000089198 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16490974

  3. Tahirović, H, et al., & Gnat, D (2009). Maternal and neonatal urinary iodine excretion and neonatal TSH in relation to use of antiseptic during caesarean section in an iodine sufficient area. Journal of pediatric endocrinology & metabolism : JPEM 22(12) 1145–1149. DOI:10.1515/jpem.2009.22.12.1145 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20333874

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)